Management of Cardiac Amyloidosis
Submission Deadline: 30 Jun 2024
Guest Editors
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Interests: amyolidosis; cardiology; heart failure; hypertension; primary aldosteronism; pulmonary hypertension; heart rhythm complexity
Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan;School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan;Graduate Institute of Medicine, Yuan Ze University, Taoyuan, Taiwan
Interests: cardiology; heart failure; atherosclerosis; biomarkers; nuclear medicine; SPECT; PET; molecular imaging
Special Issue in IMR Press journals
Special Issue in Cardio-Oncology
Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
Interests: nuclear cardiology; nuclear oncology; positron emission tomography; molecular imaging; small animal PET imaging
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Interests: heart failure; hypertension; primary aldosteronism; pulmonary hypertension; cardiomyopathy; intervention cardiology
Special Issue Information
Dear Colleagues,
Cardiac amyloidosis is characterized by the accumulation of misfolded transthyretin fibrils in the myocardium, resulting in heart failure and progressive, life-threatening diseases. Early diagnosis and a multidisciplinary approach are crucial for improving the long-term outcome for this condition. The two primary types of cardiac amyloidosis, ATTR and light chain, each require distinct diagnostic and management strategies. Although numerous novel pharmacological approaches have been developed for treating cardiac amyloidosis, their therapeutic efficacy is still being investigated. Furthermore, the optimal tools for disease monitoring and follow-up are areas of ongoing research.
This special issue entitled “Management of Cardiac Amyloidosis”, aims to highlight the diagnosis of cardiac amyloidosis and the multidisciplinary teamwork required for disease monitoring and medical management. We warmly invite you to contribute your ideas, valuable study results, or reviews for this special issue with the goal of stimulating further research in this field.
Prof. Yen-Hung Lin, Dr. Yen-Wen Wu, Dr. Mei-Fang Cheng and Dr. Cheng-Hsuan Tsai
Guest Editors
Keywords
- cardiac amyloidosis
- light chain cardiac amyloidosis
- transthyretin amyloid cardiomyopathy
Manuscript Submission Information
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.